IPF is a chronic lung disease that affects approximately 140,000 people in the U.S. Patients with IPF experience progressive breathlessness and, eventually, complete respiratory failure. Median survival is two to three years. Few treatments exist, and no treatment thus far has proven to have an effect on long-term patient survival or symptom management.
PSC is a chronic progressive disorder of unknown origin characterized by inflammation and fibrosis of the bile ducts in the liver. While PSC affects nearly 50,000 patients in the U.S., there is currently no approved therapy to treat the disease.
Unlike the few current FDA-approved therapies that treat symptoms of fibrotic disorders, Pliant is targeting the key mechanism at the root of fibrosis: exaggerated activation of transforming growth factor beta 1 (TGF-β1). TGF-β1 is a key regulator of physiological healing and pathologic fibrosis.